SCHEMBL311967

SCHEMBL311967

Nc1nc2cc(O)ccc2c2c1nc1n2CCOC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
TSHR P16473 2/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TLR7 Q9NYK1 3/20 0.41
POLB P06746 2/20 0.35
TP53 P04637 6/20 0.34
NPC1 O15118 4/20 0.34
RAB9A P51151 4/20 0.34
MAPT P10636 2/20 0.34
AR P10275 1/20 0.33
PIK3CA P42336 2/20 0.33
USP2 O75604 1/20 0.33
PRKDC P78527 1/20 0.33
MAPK1 P28482 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10123157 0.86 HRH4 (0.39) ALDH1A1ALOX15TLR7POLBTP53
SCHEMBL8114384 0.83 KDM4E (0.46) ALDH1A1GAAHPGDHSD17B10TLR7
SCHEMBL311081 0.79 PRKDC (0.43) ALDH1A1TP53NPC1RAB9AMAPT
SCHEMBL12097423 0.77 POLB (0.39) ALDH1A1TSHRTLR7POLBTP53
SCHEMBL311219 0.77 ALDH1A1 (0.47) ALDH1A1HPGDPOLBTP53NPC1
SCHEMBL202181 0.76 TLR7 (0.41) ALDH1A1TSHRGAAHPGDALOX15
SCHEMBL1775932 0.76 TLR7 (0.41) ALDH1A1TSHRGAAHPGDALOX15
SCHEMBL1233100 0.74 TLR7 (0.40) ALDH1A1TSHRGAAHPGDALOX15
SCHEMBL1773415 0.73 TLR7 (0.44) ALDH1A1TSHRGAAHPGDALOX15
SCHEMBL12165325 0.73 PIK3CD (0.42) ALDH1A1GAAHPGDHSD17B10TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093390-B2 Substituted fused [1,2]imidazo[4,5-C] ring compounds and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-01-10 US disclosed
US-20090005371-A1 Substituted Fused [1,2]Imidazo[4,5-C] Ring Compounds and Methods 3M INNOVATIVE PROPERTIES COMPANY 2009-01-01 US disclosed
EP-1845986-A2 SUBSTITUTED FUSED [1,2]IMIDAZO[4,5-C]RING COMPOUNDS AND METHODS Coley Pharmaceutical Group, Inc. (US) 2007-10-24 EP disclosed
WO-2006086633-A2 SUBSTITUTED FUSED [1,2]IMIDAZO[4,5-C] RING COMPOUNDS AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2006-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005371-A1 Substituted Fused [1,2]Imidazo[4,5-C] Ring Compounds and Methods IL2, IFNG, IL4 ALDH1A1 890/4885TSHR 2005/4885GAA 958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.